Bernard R. Tyrrell
Profile
Bernard R.
Tyrrell worked as the Senior Vice President of Sales & Marketing at EpiCept Corp.
and as the SVP of North American Sales & Marketing at Delcath Systems, Inc. He received an undergraduate degree from Massachusetts College of Pharmacy & Health Science and an MBA from Bryant University.
Former positions of Bernard R. Tyrrell
| Companies | Position | End |
|---|---|---|
| DELCATH SYSTEMS, INC. | Sales & Marketing | - |
EpiCept Corp.
 EpiCept Corp. Pharmaceuticals: MajorHealth Technology EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY. | Sales & Marketing | - |
Training of Bernard R. Tyrrell
| Massachusetts College of Pharmacy & Health Science | Undergraduate Degree |
| Bryant University | Masters Business Admin |
Experiences
Positions held
Linked companies
| Listed companies | 1 |
|---|---|
| DELCATH SYSTEMS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
EpiCept Corp.
EpiCept Corp. Pharmaceuticals: MajorHealth Technology EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY. | Health Technology |
- Stock Market
- Insiders
- Bernard R. Tyrrell